1YTop 25% of the group
Rank 16 of 63 funds
Return +22.81%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 16No. 1 is SCBGENOME(E) +62.13%
Bualuang Global Health Care Super Savings Fund
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
BCARESSF invests through the master fund Wellington Global Health Care Equity Fund 98.71%
This fundBCARESSF
The fund that actually investsWellington Global Health Care Equity FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY8.39%
Merck & MRK5.43%Fact sheet checked on 27 Oct 2026 · Top 6 shown, the rest grouped as Other · per Wellington fact sheet
Over the past year it was in the top 25% of its group; over 3 years it returned +9.27% per year (Better than half the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | MAX |
|---|---|---|---|---|---|---|---|---|
| +14.76% | +1.98% | +5.05% | +8.18% | +8.20% | +17.31% | +22.94% | +30.48% | +20.12% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar |
|---|
Largest drawdown in the selected period −25.33% Previous peak 16 Jul 2024 (NAV 11.0735) → Trough 14 May 2025 (NAV 8.2686) · Back to the previous peak on 26 Jun 2026, after 1 year 1 month
Currently −0.51% from the peak NAV of 12.0732 (30 Oct 2026)
Over 3 years, BCARESSF returned 0.62 per unit of volatility, ranking 13 of 37 funds · The highest is TBIOTECH (0.88)
กองทุนมีนโยบายลงทุนในต่างประเทศ โดยเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน โดยจะเน้นลงทุนในหน่วยลงทุนของ Wellington Global Health Care Equity Fund (กองทุนหลัก) ชนิดหน่วยลงทุน Class S (Accum-USD) โดยเฉลี่ยรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน… Its largest holdings are Wellington Global Health Care Equity Fund 98.71% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 9 Nov 2022, its NAV has fallen as much as −25.33% from its peak.
Actual total expense ratio (TER) 1.23% a year, against a ceiling of 2.41%. Management fee 1.07%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 500 THB, subsequent purchases 500 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 44.81% of the value of its foreign investments was hedged
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
AstraZeneca AZN.L3.85%
Unitedhealth Group UNH2.86%
ABBVIE ABBV2.47%
GSK2.47%
Intuitive Surgical ISRG2.37%
Vertex Pharmaceuticals VRTX2.27%
Elevance Health ELV2.27%Eli Lilly and Co LLYDiabetes and weight-loss drugs
Merck & MRKHospitals, medicines and medical equipment
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
AstraZeneca AZN.LHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
ABBVIE ABBVHospitals, medicines and medical equipment
GSK GSKHospitals, medicines and medical equipment
Intuitive Surgical ISRGHospitals, medicines and medical equipment
Makes cystic fibrosis drugs and a gene-editing therapy for thalassaemia
Elevance Health ELVHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (98.71% as of 30 Sep 2026) × each stock's weight in the master fund · fact sheet from Wellington · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | −0.1 | +1.5 | −3.7 | +0.1 | +1.4 | +8.1 | −1.1 | +4.9 | −2.8 | +6.7 | −0.5 | · | +14.8* |
| 2025 | +3.8 | −1.0 | −4.8 | −1.2 | −5.0 | +0.7 | −0.9 | +3.8 | +4.2 | +6.0 | +9.1 | −1.8 | +12.6 |
| 2024 | +1.5 | +2.8 | +2.1 | −3.4 | +1.8 | +2.7 | +0.7 | +2.3 | −6.8 | −2.3 | +0.3 | −7.6 | −6.6 |
| 2023 | −2.0 | −1.8 | −0.3 | +3.2 | −0.8 | +3.3 | −0.9 | −0.9 | −2.9 | −5.2 | +4.4 | +5.1 | +0.8 |
| 2022 | · | · | · | · | · | · | · | · | · | · | +1.2 | −2.4 | −1.2* |
